Viridian's Lumvoa is the first FDA-approved rival to Amgen's Tepezza in thyroid eye disease (TED), approved in June 2026 with a label covering both active and chronic disease stages.
Lumvoa offers a shorter treatment course (five infusions over 12 weeks vs. Tepezza's eight infusions over about 24 weeks), with similar anti-IGF-1R mechanism and comparable price (around $450,000 per course).
Analysts believe Lumvoa is a strong competitor due to its shorter regimen, broader label, and strong clinical data, but both Lumvoa and Tepezza may face future pressure from a subcutaneous (SC) version of Tepezza and other pipeline therapies.
Sources:
Viridian may have edge over Amgen in eye drug showdown ...
Thyroid Eye Disease: The $200,000 Drug Finally Gets a Rival
FDA clears Viridian's Tepezza rival for thyroid eye disease
FDA Approves Lumvoa for Thyroid Eye Disease, Puts Tepezza...
Viridian Therapeutics (VRDN) challenges Amgen's Tepezza with broader
Weekly Roundup - PHARMA - 1 July 2026 - LinkedIn
Viridian獲得首個FDA批准，將挑戰安進的Tepezza在甲狀腺眼病領域的地位
Lumvoa (Veligrotug) vs Tepezza for Thyroid Eye Disease Treatment
Jun 26, 2026 | FDA Approves Viridian for Thyroid Eye Disease
FDA Approves Viridian's Lumvoa for Thyroid Eye Disease ... - BioIntel
Business News Today Reporter's Post - LinkedIn
The Only Drug for Thyroid Eye Disease Cost $343,000 and Had No Competition. That Just Changed.